Canadian pharmaceutical to expand

Garza, Daniel R.
March 1999
Caribbean Business;3/4/1999, Vol. 27 Issue 8, p2
Focuses on the additional employees projected by Biovail Corp. for its pharmaceutical manufacturing facility in Puerto Rico following the approval of its hypertension drug by the United States Food & Drug Administration (FDA).


Related Articles

  • Biovail Strengthens Its Delivery Platform With Pharma Pass Buy.  // Chemical Market Reporter;12/16/2002, Vol. 262 Issue 22, p2 

    Reports the acquisition of the Pharma Pass LLC and Pharma Pass SA by Biovail Corp. Financial terms of the deal; Acquisition of two drug delivery technology by the company; Expansion of the company's pipeline potential with numerous product development programs.

  • Teva Pharmaceutical reaches marketing pact with Biovail Corp. Popolillo, Melissa C. // Drug Store News;3/16/98, Vol. 20 Issue 5, pCP32 

    Discusses the agreement between Teva Pharmaceutical Industries and Biovail Corp. regarding an exclusive marketing and product development. Marketing rights given to Teva for Biovail's on-the-way controlled-lease eight generic products; Details on the agreement; Comment of Eugene Melnyk of...

  • Active Pharmaceutical Ingredient Watch.  // Chemical Market Reporter;4/22/2002, Vol. 261 Issue 16, p8 

    Presents updates on the U.S. pharmaceutical industry as of April 2002. Company to be acquired by Biovail Corp.; Net income posted by Genzyme General; Agreement signed by GlaxoSmithKline plc.

  • STEALTH PHARMAS.  // Pharmaceutical Executive;Apr2007, Vol. 27 Issue 4, p54 

    The article provides information about the financial performance of biotechnological firms, specialty parmaceutical companies and generics makers that make up the so-called Not Big Pharma. There are 15 companies which have been selected and ranked to show how these shadow pharmaceutical firms...

  • NEW INDICATIONS.  // Drug Topics;5/3/2004, Vol. 148 Issue 9, p63 

    Features various drugs with new indications. Medical condition addressed by Vioxx from Merck & Co. Inc.; New indication for Cardizem LA developed by Biovail Corp.

  • Metformin Extended Release – DepoMed: Metformin, Metformin Gastric Retention, Metformin GR. Adis International Limited // Drugs in R&D;2004, Vol. 5 Issue 4, p231 

    Metformin extended release [Glumetzaâ„¢, metformin hydrochloride, metformin gastric retention, metformin GRâ„¢] is a proprietary once-a-day formulation of metformin hydrochloride under development with DepoMed for the treatment of diabetes. In May 2002, DepoMed licensed manufacturing and...

  • Active Pharmaceutical Ingredient Watch.  // Chemical Market Reporter;6/24/2002, Vol. 261 Issue 25, p13 

    Presents news briefs on the pharmaceutical industry as of June 2002. Percentage growth of the stocks of Biogen Inc.; Market approval letter received by Biovail Corp. from the U.S. Food and Drug Administration for the hypertension drug Cardizem XL; Investment of GlaxoSmithKline PLC for a...

  • Biovail receives court's favor in Tiazac action.  // PharmaWatch: Biotechnology;May 2005, Vol. 4 Issue 5, p19 

    Reports that Biovail Corp. has revealed that a United States court decision has ruled in the company's favor in two related class action cases concerning its hypertension and angina drug, Tiazac. Allegation of complainants on the delay in entry of a generic product into the market caused them to...

  • In Brief.  // Chemical Market Reporter;10/01/2001, Vol. 260 Issue 12, p10 

    Presents news in life science business as of October 2001. Biotechnology venture formed by Eli Lilly & Co.; Why Vertex Pharmaceuticals Inc. has suspended clinical development of the rheumatoid arthritis compound VX-745; Plan of Biovail Corp. regarding the court decision in favor of Andrx over...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics